Alpha 2.0
Login Register
» Authors » Yannick Hoffert

Yannick Hoffert

Explore the profile of Yannick Hoffert including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 2
Followers 0
Related Specialties
Pharmacology
Gastroenterology
Neurology
Top 10 Co-Authors
Erwin Dreesen
Dirk Kuypers
Tim Vanuytsel
Robin Vos
Nada Dia
Johan Van Cleemput
Jef Verbeek
Bram Verstockt
Katrien Lagrou
Marian Klose
Published In
Clin Pharmacokinet
Pharmaceutics
Neurogastroenterol Motil
Infection
CPT Pharmacometrics Syst Pharmacol
Affiliations
Soon will be listed here.
Recent Articles
1.
Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis
Hoffert Y, Ferrante M, Verstockt B, Dreesen E
Lancet Gastroenterol Hepatol . 2024 Dec; 10(1):18-19. PMID: 39674216
No abstract available.
2.
Anidulafungin exposure and population pharmacokinetics in critically ill patients with invasive candidiasis
Elkayal O, Hoffert Y, Mertens B, Van Daele R, Lagrou K, Wauters J, et al.
Infection . 2024 Dec; PMID: 39641856
Purpose: Anidulafungin is recommended as a first-line treatment for invasive Candida infections in critically ill patients. Pharmacokinetic (PK) variability is large in critically ill patients, potentially compromising pharmacokinetic-pharmacodynamic (PKPD) target...
3.
Correction: Model-Informed Precision Dosing of Tacrolimus: A Systematic Review of Population Pharmacokinetic Models and a Benchmark Study of Software Tools
Hoffert Y, Dia N, Vanuytsel T, Vos R, Kuypers D, Van Cleemput J, et al.
Clin Pharmacokinet . 2024 Oct; 63(10):1511. PMID: 39446277
No abstract available.
4.
Model-Informed Precision Dosing of Tacrolimus: A Systematic Review of Population Pharmacokinetic Models and a Benchmark Study of Software Tools
Hoffert Y, Dia N, Vanuytsel T, Vos R, Kuypers D, Van Cleemput J, et al.
Clin Pharmacokinet . 2024 Sep; 63(10):1407-1421. PMID: 39304577
Background And Objective: Tacrolimus is an immunosuppressant commonly administered after solid organ transplantation. It is characterized by a narrow therapeutic window and high variability in exposure, demanding personalized dosing. In...
5.
Type 1 diabetes prevention clinical trial simulator: Case reports of model-informed drug development tool
Morales J, Klose M, Hoffert Y, Podichetty J, Burton J, Schmidt S, et al.
CPT Pharmacometrics Syst Pharmacol . 2024 Jul; 13(8):1309-1316. PMID: 38961520
Clinical trials seeking to delay or prevent the onset of type 1 diabetes (T1D) face a series of pragmatic challenges. Despite more than 100 years since the discovery of insulin,...
6.
Do we perceive sensations inside and outside of our body differently? Perceptual, emotional, and behavioral differences between visceral and somatic sensation, discomfort, and pain
Guadagnoli L, Hoffert Y, Den Hond S, Dreesen E, Van Ryckeghem D, Van Damme S, et al.
Neurogastroenterol Motil . 2024 Mar; 36(6):e14787. PMID: 38523349
Background: Experimental research evaluating differences between the visceral and somatic stimulation is limited to pain and typically uses different induction methods for visceral and somatic stimulation (e.g., rectal balloon distention...
7.
Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates
Berckmans Y, Hoffert Y, Vankerckhoven A, Dreesen E, Coosemans A
Pharmaceutics . 2023 Jul; 15(7). PMID: 37513979
The lethality of patients with ovarian cancer (OC) remains high. Current treatment strategies often do not lead to the desired outcome due to the development of therapy resistance, resulting in...